Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

IMMUNE RESPONSIVENESS TO THE IMMUNODOMINANT RECOMBINANT ENVELOPE EPITOPES OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-1 AND TYPE-2 IN DIVERSE GEOGRAPHIC POPULATIONS JOURNAL OF INFECTIOUS DISEASES Buckner, C., ROBERTS, C. R., Foung, S. K., Lipka, J., Reyes, G. R., Hadlock, K., Chan, L., GONGORABIACHI, A., Hjelle, B., Lal, R. B. 1992; 166 (5): 1160-1163

Abstract

The heterogeneity of immune responsiveness to the immunodominant epitopes of human T lymphotropic virus (HTLV) types I (MTA-1(162-209)) and II (K-55(162-205)) were determined in natural infections with HTLV-I and -II from diverse geographic areas (n = 285). Of the HTLV-I specimens confirmed by polymerase chain reaction (PCR), all North American (n = 37) and Peruvian (n = 19) specimens reacted with MTA-1. Of HTLV-II specimens confirmed by PCR, 44 (96%) of 46 from North American blood donors, 28 (97%) of 29 from native Americans, and all from intravenous drug users (n = 29) reacted with K-55. Specimens from other geographic areas (Peru, 30; Brazil, 4; Mexico, 10; Italy, 5; Somalia, 13; Ethiopia, 17; Japan, 32; and Jamaica, 15) all reacted either with MTA-1 or K-55. By synthetic peptide-based serologic typing, all of these specimens could be typed as HTLV-I or -II. In addition to the direct implications of these findings for diagnostic purposes, these data provide indirect evidence for the conservation of immunodominant HTLVenv epitopes in diverse geographic populations.

View details for Web of Science ID A1992JV01500031

View details for PubMedID 1383353